Loading patent…
AssigneeAdicet Bio, Inc.
InventorsAya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
Estimating the term…
The present invention relates to methods for the selective expansion of γδ T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched γδ T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
An ex vivo method for producing an enriched δ1 γδ T-cell population from an isolated mixed cell population without prior selection of γδ T-cells and/or depletion of non-γδ T-cells, and under culture conditions that do not comprise IL-4 and wherein said cell population has not been exposed to exogenous IL-4 prior to expansion, said method comprising directly contacting the mixed cell population with at least one antibody that selectively expands δ1 T-cells without significant expansion of δ2 T-cells by binding to an epitope specific to a δ1 variable region of a δ1 TCR to provide clinically-relevant levels of an enriched δ1 γδ T cell population, wherein the at least one antibody comprises a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs:
The method of any one of the preceding claims, wherein said method does not comprise expanding the enriched δ1 γδ T-cell population by an antigen presenting cell or an aminophosphate.
Dependencies are inferred from the claim text.